Evaluating the impact of pre-diagnostic use of statins and testosterone replacement therapy on mortality outcomes in older men with hormone-related cancers: Surveillance, Epidemiology, and End Results-Medicare 2007-2015.
Maryam R HussainOmer AbdelgadirEfstathia PolychronopoulouKonstantinos K TsilidisLaith AlzweriAlejandro Villasante-TezanosJacques BaillargeonSteven CanfieldYong-Fang KuoDavid S LopezPublished in: Andrology (2024)
Pre-diagnostic use of statins and testosterone replacement therapy showed a survival benefit with reduced mortality in high-grade hormone-related cancer patients (only statins) and aggressive prostate cancer patients in both statistical models. Findings of testosterone replacement therapy use in aggressive prostate cancer settings could facilitate clinical trials. Further studies with extended follow-up periods are needed to substantiate these findings.
Keyphrases
- replacement therapy
- prostate cancer
- smoking cessation
- high grade
- cardiovascular disease
- clinical trial
- cardiovascular events
- risk factors
- radical prostatectomy
- public health
- middle aged
- low grade
- randomized controlled trial
- metabolic syndrome
- coronary artery disease
- healthcare
- adipose tissue
- young adults
- community dwelling
- insulin resistance
- drug induced
- skeletal muscle